Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Accelerate to discover
Related topics
The draft genome sequence of the Japanese rhinoceros beetle Trypoxylus dichotomus septentrionalis
Nov 30, 2023
The SageHLS instrument was used to size select DNA between 50-80 kb for 10X Genomics Chromium linked read analysis.
Factors Affecting Petri Dish Condensation in Tissue Culture (CU) Chambers
Nov 29, 2023
In this report, we will investigate the effects of infrared lighting, light intensity, stacking, as well as constant...
Visualization of spatial distribution of hemoglobin with various oxygen saturations in small animals
Nov 28, 2023
With the aid of our uniquely developed device and analysis software, our primary objective is to map the spatial...
A fluorescent reporter system for anaerobic thermophiles
Nov 27, 2023
Anaerobic microorganisms are key effectors for the sustainable production of biofuels and biochemicals, as they...
Vizgen webinar: spatial relationships in Developmental Biology
Nov 21, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, In this webinar we will...
Validation of an orthotopic non-small cell lung cancer mouse model to use in radiotherapy studies
Oct 30, 2023
The use of pre-clinical orthotopic mouse models is essential for the development of novel therapies targeting solid...
Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy
Oct 20, 2023
To assess tumour growth, mice were imaged using the AMI-HTX bioluminescent imaging system (Spectral Instruments...
IVIM in vivo platform to study efficacy of adoptive and anti-PD- 1- based immunotherapy
Oct 18, 2023
Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-
based immunotherapy...
Aug 9, 2016
At the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Anna Wu, Ph.D., professor and chair of the department of molecular and medical pharmacology, has been engineering antibodies for both therapeutic and imaging purposes. Antibodies meant for imaging, she points out, reflect a slightly different set of engineering characteristics.
Dr. Wu works with colleagues at UCLA and ImaginAb (a company she co-founded in 2007 and now serves as chief scientist) to engineer labeled antibodies. Because Dr. Wu in interested in advancing positron emission tomography (PET) imaging, she is engineering antibodies that incorporate positron-emitting radionucleotides.
“Each imaging modality has its strengths and weaknesses,” notes Dr. Wu. “Magnetic resonance imaging (MRI) gives you anatomical and physiological imaging, but it doesn’t have the sensitivity of PET. PET has a higher resolution and sensitivity compared to single-photon emission computed tomography (SPECT), but it has lower resolution than MRI or CT.”
Dr. Wu has chosen PET because it fits well with her antibody fragments (called minibodies and diabodies) in a process coined immunoPET. She favors PET because it can, she says, be combined with the specificity of antibodies.
“One of the key features of antibodies is they have very long circulating half-lives,” she points out. “Antibodies stay in the blood for days to weeks.” To match the half-lives of antibodies, she and others have been testing longer-lived positron emitters, such as zirconium-89. “The fluorine-18 everyone uses has a two-hour half-life, so it’s a challenge to make a fragment that targets and clears quickly enough to image.” Zirconium-89, in contrast, has a half-life that is a little over three days.
Related technologies: PET, SPECT, CT
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com